Lungenklinik Hemer Deutscher Gemeinschafts-Diakonieverband GmbH — Clinical Trial Site

35 Registered trials

15 Currently recruiting

Organisation

Lungenklinik Hemer Deutscher Gemeinschafts-Diakonieverband GmbH

Location

Hemer, Germany

Identifier

ORG-100043982

Address

Theo-Funccius-Strasse 1, 58675, Germany

Departments

--
Center for Pneumology and Thorac Sugery, Department of Pneumology
Center for Pneumology and Thoracic surgery
Department of Pneumology
Department of Pulmology III
des Deutschen Gemeinschafts-Diakonieverbandes GmbH
Hämatologie/Onkologie
Lungenklinik
Lungenklinik Hemer
Lungenklinik Hemer Deutscher Gemeinschafts-Diakonieverband GmbH
Lungenkrebszentrum
NA
Oncology
Onkologie
Onkologie und Onkologische Palliativmedizin
Onkologie und Palliativmedizin der Lungenklinik Hemer
Pneumologie
Pneumologie III Thorakale Onkologie
Pneumology
Pulmology III
Thoracic oncology
Thorakale Onkologie
Thorakale Onkologie und onkologische Palliativmedizin
Zentrum für Pneumologie und Thoraxchirurgie

Clinical trials at this site (35)

Search interface

Additional chemotherapy for EGFRm patients with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib 1st-line t… Ended

2024-517965-18-00 Advanced NSCLC with common EGFR-Mutation 4 2021-11-11
A study on the efficacy and safety of cisplatin/etoposide and concomitant radiotherapy in combination with durvalumab, an immunotherapy, in … Ended

2024-513433-20-00 Limited Disease Small Cell Lung Cancer 4 2020-12-16
ABP - Advancing Brigatinib Properties in anaplastic lymphoma kinase positive nonsmall cell lung cancer (ALK+ NSCLC) patients by deep phenoty… Ended

2024-513947-94-00 locally advanced (stage III) and not suitable for curat 4 2020-03-30
Prospective Phase-II Trial of induction chemotherapy and chemoradiotherapy plus/minus the PD-L1 antibody durvalumab followed by surgery or d… Ended

2024-513039-26-00 non-small cell lung cancer stages IIIA (N2) and selecte 4 2019-11-25
Chemo +/- Pembrolizumab (MK-3475) as Perioperative Therapy for Stage II, IIIA-Resectable IIIB (N2) NSCLC Ended

2023-504820-24-00 Neoadjuvant/Adjuvant treatment for participants with Re 5 2018-03-21
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lun… Ended

2023-505981-26-00 Non−Small Cell Lung Cancer 5 2015-11-20
A study to test whether BI 1819479 improves lung function in people with idiopathic pulmonary fibrosis (IPF). Ended

2023-508395-11-00 idiopathic pulmonary fibrosis 4 2024-09-10
A study to find out whether BI 1015550 improves lung function in people with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) Ended

2024-512803-37-00 Progressive Fibrosing Interstitial Lung Diseases (PF-IL 5 2022-10-05
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants wit… Ended

2023-508443-40-00 Lung Cancer, Non-Small Cell 5 2020-12-18
Thoracic Radiotherapy plus Durvalumab in Elderly and/or frail NSCLC stage III patients unfit for chemotherapy - Employing optimized (hypofra… Ended

2024-513948-28-00 unresectable stage III NSCLC (Non–small-cell lung cance 4 2020-05-08
A Study of Nivolumab and Ipilimumab Combined with Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV … Ended

2023-508757-75-00 Stage IV Non-Small Cell Lung Cancer (NSCLC) 5 2017-09-18